Phase 2 Crohn's Disease and Colitis Trial, Recruiting NCT07113522 Sponsor: Mirador Therapeutics, Inc. Condition: Crohn's Disease and Colitis
Back to Crohns Disease And Colitis

Phase 2 Crohn's Disease and Colitis Trial, Recruiting

NCT07113522
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

For people with Crohn's Disease:

  • You have been diagnosed with Crohn's Disease, confirmed through a camera examination of your gut (endoscopy) and tissue samples (biopsy)
  • Your Crohn's Disease is considered moderately to severely active, based on specific scoring tools used by doctors to measure symptoms and gut inflammation
  • You meet certain requirements about being on stable medications before joining (confirm with trial site)

For people with Ulcerative Colitis:

  • You have been diagnosed with Ulcerative Colitis, confirmed through a camera examination of your gut (endoscopy) and tissue samples (biopsy)
  • Your Ulcerative Colitis is considered moderately to severely active, based on a specific scoring tool used by doctors to measure your condition
  • You meet certain requirements about being on stable medications before joining (confirm with trial site)

Who may not be able to join:

For people with Crohn's Disease:

  • You have been diagnosed with a type of bowel inflammation that doctors cannot clearly identify as either Crohn's Disease or Ulcerative Colitis
  • You have or may have a pocket of infection (abscess) inside your abdomen or around your back passage
  • You have had large portions of your small intestine removed (more than 100 cm total), or more than two sections of your large intestine removed
  • Your Crohn's Disease affects only the stomach, upper small intestine, or the area around the back passage, without involving the lower small intestine or large intestine

For people with Ulcerative Colitis:

  • You currently have, or have had in the last 6 months, a severe flare-up of your colon, a dangerously swollen colon, or a hole in your bowel
  • You currently have a stoma (a surgically created opening in the abdomen for waste) or are likely to need one
  • You have received steroid medication given directly into a vein (IV) within the 14 days before or during the screening period
  • You have had your entire large intestine and rectum, or most of your large intestine, surgically removed

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 7 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 844-206-4980

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Mirador Therapeutics, Inc.
Registry
ClinicalTrials.gov
Start date
26 June 2025
Est. completion
30 April 2027

Where this trial is recruiting

🇨🇦 Canada 🇬🇪 Georgia Moldova 🇺🇦 Ukraine 🇺🇸 United States

Primary endpoints

Assess the proportion of participants reporting treatment emergent adverse events (TEAEs), serious adverse events (SAEs), adverse events (AEs) leading to discontinuation, and markedly abnormal laboratory values; Assess the Proportion of Participants with Endoscopic Response (CD); Assess the Proportion of Participants Endoscopic Improvement (UC); Assess the Proportion of Participants with Clinical Remission (CD); Assess the Proportion of Participants with Clinical Remission (UC)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov